GlassScriptPhysician profile
John Daniel Kornmayer
NPI 1992878227
$4,417.44
in general payments reported to CMS, 2019-2025
25 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $483 · 2021: $1,224 · 2022: $682 · 2023: $219 · 2024: $219 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $817.74 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $728.37 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $503.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $386.00 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $368.63 | 2019-2024 | Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $264.18 | 2022 | |
| Pfizer INC. | $185.74 | 2019-2023 | |
| Abbvie INC. | $177.17 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $140.45 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $133.42 | 2019-2021 | |
| Esperion Therapeutics, INC. | $119.15 | 2020 | |
| Astellas Pharma US INC | $112.26 | 2021 | |
| Allergan, INC. | $79.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $63.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.19 | 2019-2023 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $59.23 | 2022-2023 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $45.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $36.05 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.83 | 2019-2021 | |
| Lilly USA, LLC | $25.31 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.69 | 2019 | |
| Indivior INC. | $14.39 | 2019 | |
| Kaleo, INC. | $14.04 | 2019 | |
| Azurity Pharmaceuticals, INC. | $12.13 | 2022 | |
| Amarin Pharma, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kornmayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.